Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA343130 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Purpose: To gain insight into genomic and trancriptomic subtypes of ductal carcinomas in situ of the breast (DCIS). Results: Thirty-two DCIS exhibited a luminal phenotype; 21were ERBB2 positive, and 4 were ERBB2/estrogen receptor (ER) negativewith1harboring a bona fide basal-like phenotype.Based on a CGHanalysis, genomic types were identified in this series of DCISwith the 1q gain/16q loss combination observed in 3 luminal DCIS, themixed amplifier pattern including all ERBB2,12 luminal and 1ERBB2/ER- DCIS, and the complex copy number alteration profile encompassing 14 luminal and 1ERBB2/ER- DCIS. Eight cases (8 of 57; 14%) presented aTP53 mutation, all being amplifiers. Unsupervised analysis of gene expression profiles of 26 of the 57 DCIS showed that luminal and ERBB2-amplified, ER-negative cases clustered separately.We further investigated the effect of high and low copy number changes on gene expression. Strikingly, amplicons but also low copy number changes especially on 1q, 8q, and 16q in DCIS regulated the expression of a subset of genes in a very similar way to that recently described in invasive ductal carcinomas. Conclusions: These combined approaches show that the molecular heterogeneity of breast ductal carcinomas exists already in in situ lesions and further indicate that DCIS and invasive ductal carcinomas share genomic alterations with a similar effect on gene expression profile.
2016-12-22 | GSE92697 | GEO
Project description:we describe a mRNA profiling analysis of matched ductal carcinoma in situ and invasive duct carcinoma components of FFPE breast carcinomas with the purpose to identify potential prognostic markers
2016-08-01 | GSE72205 | GEO
Project description:We describe a miRNA profiling analysis of matched ductal carcinoma in situ and invasive duct carcinoma components of FFPE breast carcinomas with the purpose to identify potential prognostic markers
2016-12-01 | GSE39567 | GEO
Project description:In a previous study of ductal carcinoma in situ (DCIS) of the breast (see GEO accession #GSE7882) we identified six genes at chromosome 17q21.33 that were over-expressed in high grade cases, and showed a correlation between expression level and gene copy number. The aim of this study was to determine whether potential drivers of high grade breast cancer growth could be identified at 17q21.33. High resolution comparative genomic hybridisation was used to interrogate genomic aberrations in laser capture microdissected samples of ductal carcinoma in situ.
2013-10-15 | GSE33249 | GEO
Project description:we describe a mRNA profiling analysis of matched ductal carcinoma in situ and invasive duct carcinoma components of FFPE breast carcinomas with the purpose to identify potential prognostic markers mRNA extracted from 15 matched DCIS/IDC and 14 pure DCIS preparations was profiled using Illumina DASL platform
2016-08-01 | E-GEOD-72205 | biostudies-arrayexpress
Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes in borderline and invasive components of serous carcinoma. Borderline and invasive tumor components were profiled from patients with LGSC
2014-10-01 | E-GEOD-57270 | biostudies-arrayexpress
Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes in borderline and invasive components of serous carcinoma.
2014-10-01 | GSE57270 | GEO
Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted.We sought to identify differences in genomic copy number changes between co-existing borderline and invasive components of serous carcinoma. Paired co-existing borderline and invasive tumor components were sampled and profiled from formalin-fixed paraffin embedded tumors from 6 patients
2014-10-01 | E-GEOD-57276 | biostudies-arrayexpress
Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes between co-existing borderline and invasive components of serous carcinoma. Paired co-existing borderline and invasive tumor components of ovarian serous carcinoma were sampled and profiled from tumors from 7 patients
2014-10-01 | E-GEOD-57279 | biostudies-arrayexpress
Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes between co-existing borderline and invasive components of serous carcinoma.
2014-10-01 | GSE57279 | GEO